[{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","route":"/companies/insilico-medicine/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts","type":"changed","fields":[{"field":"summary","before":"\"Largest Hong Kong biotech IPO of 2025 (HKD 2.28B). Pipeline of 31 nominated candidates with 13 IND clearances; oncology assets include ISM6166 (pan-KRAS) and ISM6331 (pan-TEAD, phase 1 data at ESMO 2026 in mesothelio...","after":"\"Insilico's 2025 listing was the largest Hong Kong biotech IPO of the year (HKD 2.28B). Pipeline of 31 nominated candidates with 13 IND clearances; oncology assets include ISM6166 (pan-KRAS) and ISM6331 (pan-TEAD, pha..."}]},{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","route":"/companies/insilico-medicine/","commit":"335b83f6e7","date":"2026-09-06","author":"Jude Gomila","message":"Expand companies: Katsutake map imports and 44 frontier oncology companies; add frontier technologies (programmable DNA-targeting, fragmento","file":"src/data/companies.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"technologies"},{"field":"targets"},{"field":"cancers"},{"field":"links"}]}]